Figure 1
Expression of ABC-type transporters in cell lines and patients’ primary cells. (a) RNA expression of ABCB1, ABCC2 and ABCG2 transporter in AMO-1, AMO-BTZ and AMO-CFZ cell lines. (b) Expression of ABCB1, ABCC2 and ABCG2 transporter in ARH77, ARH-BTZ and ARH-CFZ cell lines. (c) Western blot validation of the overexpression of ABCB1 transporter in AMO-1 and ARH77 cell lines sensitive to PIs and their resistant counterparts. (d) Expression of ABCB1, ABCC2 and ABCG2 in primary patient’s sample: MMs, sensitive to CFZ; MMr, resistant to CFZ treatment. (e) Expression of ABCB1 and ABCG2 transporters in primary BTZ (BTZ-R) (n=33) and CFZ (CFZ-R) (n=29) resistant, newly diagnosed (NDMM) (n=1309) myeloma patients and in circulating PB–PC (n=44). Significant values <0.05 are marked with an asterisk (*).
